TPI 287

Drug Profile

TPI 287

Alternative Names: ARC-100; NBT 287; TPI-287

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tapestry Pharmaceuticals
  • Developer Cortice Biosciences; H. Lee Moffitt Cancer Center and Research Institute; Tapestry Pharmaceuticals; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; Van Andel Research Institute
  • Class Antineoplastics; Taxanes
  • Mechanism of Action Microtubule protein modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Glioblastoma
  • Phase I/II Malignant melanoma
  • Phase I Alzheimer's disease; Corticobasal degeneration; Non-small cell lung cancer; Progressive supranuclear palsy
  • No development reported Cancer; Medulloblastoma; Neuroblastoma
  • Discontinued Pancreatic cancer; Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in USA (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Corticobasal-degeneration in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top